Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia

Journal of Immunology

Volumn 180, Issue 11, 2008, Pages 7714-7720

  Wootla, Bharath ^a,b,c   Dasgupta, Suryasarathi ^a,b,c   Dimitrov, Jordan D ^a,b,c   Bayry, Jagadeesh ^a,b,c   Lévesque, Hervé ^d   Borg, Jeanne Yvonne ^e   Borel Derlon, Annie ^e   Rao, Desirazu N ^g   Friboulet, Alain ^f   Kaveri, Srinivas V ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^g INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; IMMUNOGLOBULIN G; ALLOANTIBODY; AUTOANTIBODY; CATALYTIC ANTIBODY;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HEMOPHILIA; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; ADULT; AGED; BLOOD; FEMALE; HEMOPHILIA A; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN G; ISOANTIBODIES; MALE; MIDDLE AGED;

EID: 47249156490     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.11.7714     Document Type: Article

References (42)

1. Kessler, C. M. 2000. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica 85: 57-61.
2. Franchini, M., G. Gandini, T. Di Paolantonio, and G. Mariani. 2005. Acquired hemophilia A: a concise review. Am. J. Hematol. 80: 55-63.
3. Collins, P. W., S. Hirsch, T. P. Baglin, G. Dolan, J. Hanley, M. Makris, D. M. Keeling, R. Liesner, S. A. Brown, and C. R. Hay. 2007. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109: 1870-1877.
4. Green, D.I991. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am. J. Med. 91: 14S-19S.
5. Morrison, A. E., C. A. Ludlam, and C. Kessler. 1993. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81: 1513-1520.
6. Mannucci, P. M., and E. G. Tuddenham. 2001. The hemophilias: from royal genes to gene therapy. N. Engl. J. Med. 344: 1773-1779.
7. Lavigne-Lissalde, G., J. F. Schved, C. Granier, and S. Villard. 2005. Anti-factor VIII antibodies: a 2005 update. Thromb. Haemostasis 94: 760-769.
8. Lacroix-Desmazes, S., A. Moreau Sooryanarayana, C. Bonnemain, N. Stieltjes, A. Pashov, Y. Sultan, J. Hoebeke, M. D. Kazatchkine, and S. V. Kaveri. 1999. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med. 5: 1044-1047.
9. Lacroix-Desmazes, S., J. Bayry, N. Misra, M. P. Hom, S. Villard, A. Pashov, N. Stieltjes, R. d'Oiron, J. M. Saint-Remy, J. Hoebeke, et al. 2002. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N. Engl. J. Med. 346: 662-667.
10. Lacroix-Desmazes, S., B. Wootla, S. Dasgupta, S. Delignat, J. Bayry, J. Reinbolt, J. Hoebeke, E. Saenko, M. D. Kazatchkine, A. Friboulet, et al. 2006. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J. Immunol. 177: 1355-1363.
11. Kasper, C. K., L. M. Aledort, and R. B. Counts. 1975. A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorrh. 34: 869-872.
12. Paul, S., L. Li, R. Kalaga, P. Wilkins-Stevens, F. J. Stevens, and A. Solomon. 1995. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragments. J. Biol. Chem. 270: 15257-15261.
13. Li, L., S. Paul, S. Tyutyulkova, M. D. Kazatchkine, and S. Kaveri. 1995. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154: 3328-3332.
14. Paul, S., L. Lan, R. Kalaga, J. O'Dell, R. E. Dannenbring, Jr., S. Swindells, S. Hinrichs, P. Caturegli, and N. R. Rose. 1997. Characterization of thyroglob-ulin-directed and polyreactive catalytic antibodies in autoimmune disease. J. Immunol. 159: 1530-1536.
15. Kozyr, A. V., A. V. Kolesnikov, N. A. Zelenova, L. P. Sashchenko, S. V. Mikhalap, M. E. Bulina, A. N. Ignatova, P. V. Favorov, and A. G. Gabibov. 2000. Autoantibodies lo nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity. Appl. Bioehem. Biotechnol. 83: 255-268.
16. Baranovskii, A. G., N. A. Ershova, V. N. Buneva, T. G. Kanyshkova, A. S. Mogelnitskii, B. M. Doronin, A. N. Boiko, E. I. Gusev, O. O. Favorova, and G. A. Nevinsky. 2001. Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. Immunol. Lett. 76: 163-167.
17. Saveliev, A. N., D. R. Ivanen, A. A. Kulminskaya, N. A. Ershova, T. G. Kanyshkova, V. N. Buneva, A. S. Mogelnitskii, B. M. Doronin, O. O. Favorova, G. A. Nevinsky, and K. N. Neustroev. 2003. Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis. Immunol. Lett. 86: 291-297.
18. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, E. S. Aleksandrova, G. B. Telegin, O. G. Chamborant, L. L. Sidorik, S. V. Suchkov, Z. S. Alekberova, N. V. Gnuchev, and A. G. Gabibov. 2002. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J. Immunol. Methods 269: 197-211.
19. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, A. A. Belogurov, Jr., I. N. Kurkova, A. G. Petrenko, G. B. Telegin, S. V. Suchkov, S. L. Kiselev, M. A. Lagarkova, et al. 2006. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl. Acad. Sci. USA 103: 281-286.
20. Nardi, M., S. Tomlinson, M. A. Greco, and S. Karpatkin. 2001. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 106: 551-561.
21. Lacroix-Desmazes, S., J. Bayry, S. V. Kaveri, D. Hayon-Sonsino, N. Thorenoor, J. Charpentier, C. E. Luyt, J. P. Mira, V. Nagaraja, M. D. Kazatchkine, and J. F. Dhainaut, and V. O. Mallet. 2005. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA 102: 4109-4113.
22. Green, D., and K. Lechner. 1981. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb. Haemostasis 45: 200-203.
23. Sohngen, D., C. Specker, D. Bach, B. M. Kuntz, M. Burk, C. Aul, G. Kobbe, A. Heyll, K. A. Hollmig, and W. Schneider. 1997. Acquired factor VIII inhibitors in nonhemophilic patients. Ann. Hematol. 74: 89-93.
24. Shapiro, S. 1967. The immunologic character of acquired inhibitors of antihe-mophiliac globulin (Factor VIII) and the kinetics of their interaction with FVIII. J. Clin. Invest. 46: 147-156.
25. Fulcher, C. A., S. de Graaf Mahoney, and T. S. Zimmerman. 1987. Factor VIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immu-noblotting. Blood 69: 1475-1480.
26. Fulcher, C. A., K. Lechner, and S. de Graaf Mahoney. 1988. Immunoblot analysis shows changes in FVIII inhibitor chain specificity in FVIII inhibitor patients over time. Blood 72: 1348-1356.
27. Scandella, D., H. Nakai, M. Felch, W. Mondorf, I. Scharrer, L. Hoyer, and E. Saenko. 2001. In hemophilia a and autoantibody inhibitor patients: the factor viii a2 domain and light chain are most immunogenic. Thromb. Res. 101: 377-385.
28. Arai, M., D. Scandella, and L. W. Hoyer. 1989. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J. Clin. Invest. 83: 1978-1984.
29. Saenko, E. L., M. Shima, G. E. Gilbert, and D. Scandella. 1996. Slowed release of ihrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition. J. Biol. Chem. 271: 27424-27431.
30. Shima, M., D. Scandella, A. Yoshioka, H. Nakai, I. Tanaka, S. Kamisue, S. Terada, and H. Fukui. 1993. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb. Haemostasis 69: 240-246.
31. Zhong, D., E. L. Saenko, M. Shima, M. Felch, and D. Scandella. 1998. Some human inhibitor antibodies interfere with factor VIII binding to Factor IX. Blood 92: 136-142.
32. 365 of the factor VIII heavy chain. J. Clin. Invest. 82: 123-128.
33. Lubahn, B. C, J. Ware, D. W. Stafford, and H. M. Reisner. 1989. Identification of a FVIII epitope recognized by a human hemophilic inhibitor. Blood 73: 497-499.
34. Ulrich, H., E. Mundorff, B. Santarsiero, E. Driggers, R. Stevens, and P. Schultz. 1997. The interplay between binding energy and catalysis in the evolution of a catalytic antibody. Nature 389: 271-275.
35. Romesberg, F. E., B. Spiller, P. G. Schultz, and R. C. Stevens. 1998. Immuno-logical origins of binding and catalysis in a Diels-Alderase antibody. Science 279: 1929-1933.
36. Xu, J., Q. Deng, J. Chen, K. N. Houk, J. Bartek, D. Hilvert, and I. A. Wilson. 1999. Evolution of shape complementarity and catalytic efficiency from a primordial antibody template. Science 286: 2345-2348.
37. Gao, C, C. H. Lin, C. H. Lo, S. Mao, P. Wirsching, R. A. Lemer, and K. D. Janda. 1997. Making chemistry selectable by linking it to infectivity. Proc. Natl. Acad. Sci. USA 94: 11777-11782.
38. Gololobov, G., M. Sun, and S. Paul. 1999. Innate antibody catalysis. Mol. Immunol. 36: 1215-1222.
39. Planque, S., H. Taguchi, G. Burr, G. Bhatia, S. Karle, Y. X. Zhou, Y. Nishiyama, and S. Paul. 2003. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J. Biol. Chem. 278: 20436-20443.
40. Planque, S., Y. Bangale, X. T. Song, S. Karle, H. Taguchi, B. Poindexter, R. Bick, A. Edmundson, Y. Nishiyama, and S. Paul. 2004. Ontogeny of proteolytic immunity: IgM serine proteases. J. Biol. Chem. 279: 14024-14032.
41. Friboulet, A., B. Avalle, H. Debat, and D. Thomas. 1999. A possible role of catalytic antibodies in metabolism. Immunol. Today 20: 474-475.
42. Tawfik, D. S., R. Chap, B. S. Green, M. Sela, and Z. Eshhar. 1995. Unexpectedly high occurence of catalytic antibodies in MLR/lpr and SLJ mice immunized with a transition-state analog: is there a linkage to autoimmunity. Proc. Natl. Acad. Sci. USA 92: 2145-2149.